High-Throughput Cell Based Assay for the Identification of Drugs Targeting the NF-kB Signaling Pathway

Tech ID: 02-05

Summary

Researchers at National Jewish Health have developed a microscopy-based visual assay to measure the antigen-receptor activation of an intermediate molecule located upstream of NF-kB

Potential Applications

Identification of compounds as potential agents against inflammatory diseases, immune diseases and cancer

Advantages of Invention

The assay targets Bcl10, a specific intermediate protein of the NF- kB pathway, and it is compatible with epifluorescence/confocal microscopy

State of Development

Using cell lines developed in-house, National Jewish Health scientists have demonstrated that T cell receptor activation of NF-kB involves the dynamic relocalization of the signaling intermediate Bcl10. This protein movement can be visualized by confocal or epifluorescence microscopy using a fluorescent marker (such as GFP) or antibodies.


Publication

  • Schaefer, B. C., John W. Kappler, Abraham Kupfar, and Philippa Marrack. "Complex and Dynamic Redistribution of NF- B Signaling Intermediates in Response to T Cell Receptor Stimulation." Proceedings of the National Academy of Sciences 101.4 (2004): 1004-009. Print. PMID: 14724296.


Patent Status
Issued U.S. Patent #7,169,570


Inventors
Brian Schaefer, PhD, Philippa Marrack, PhD and John Kappler, PhD


Licensing Status - This technology is available for licensing.

 

For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: 303.398.1262
Fax: 303.270.2352
HilaireE@njhealth.org

Bookmark and Share

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.